Daiichi Sankyo

AstraZeneca-Daiichi Sankyo’s therapy shows response in breast cancer trials
Clinical Trials Arena
Mon, 12/12/22 - 10:26 am
AstraZeneca
Daiichi Sankyo
clinical trials
datopotamab deruxtecan
metastatic triple-negative breast cancer
breast cancer
SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla
Fierce Pharma
Fri, 12/9/22 - 10:54 am
SABCS
AstraZeneca
Enhertu
breast cancer
Daiichi Sankyo
Roche
Kadcyla
Chasing Gilead, AstraZeneca-Daiichi lay down phase 2 breast cancer data for antibody-drug conjugate
Fierce Biotech
Fri, 12/9/22 - 10:46 am
AstraZeneca
Daiichi Sankyo
breast cancer
antibody-drug conjugate
clinical trials
Gilead Sciences
Daiichi Sankyo To Transfer Yescarta Marketing Authorization In Japan To Gilead Sciences
NASDAQ.com
Thu, 12/8/22 - 10:03 am
Daiichi Sankyo
Gilead Sciences
Yescarta
Japan
The problem with Her2-low testing
EP Vantage
Mon, 11/28/22 - 07:34 pm
AstraZeneca
Daiichi Sankyo
Enhertu
breast cancer
diagnostics
HER2-low breast cancer
Cancer drugmaker Plexxikon gets new life as Opna Bio
BioPharma Dive
Tue, 11/22/22 - 10:38 am
Plexxikon
Opna Bio
rebranding
oncology
Daiichi Sankyo
Daiichi Sankyo’s Covid-19 vaccine trial meets primary endpoint
Clinical Trials Arena
Tue, 11/15/22 - 10:51 am
Daiichi Sankyo
clinical trials
MRNA
vaccines
DS-5670
COVID-19
After nearly 20 years, Cyclacel kicks phase 3 leukemia drug back to Daiichi
Fierce Biotech
Thu, 11/10/22 - 10:39 am
Cyclacel
AML
Sapacitabine
Daiichi Sankyo
Daiichi Sankyo sets new highs for AstraZeneca-partnered cancer drug Enhertu
Endpoints
Mon, 10/31/22 - 04:15 pm
Daiichi Sankyo
AstraZeneca
Enhertu
breast cancer
non-small cell lung cancer
FDA grants priority review for Daiichi Sankyo’s AML medicine
Pharmaceutical Business Review
Tue, 10/25/22 - 10:37 am
FDA
priority review
Daiichi Sankyo
quizartinib
acute myeloid leukemia
Few safe havens surface in another down quarter for biopharma
EP Vantage
Fri, 10/14/22 - 10:03 am
biopharma stocks
COVID-19
Eli Lilly
Bristol Myers Squibb
Merck
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Neurocrine
Sarepta Therapeutics
Orion
Pfizer
GSK
Roche
Moderna Therapeutics
BeiGene
BioNTech
Novavax
CureVac
The gloom deepens for biopharma stocks
EP Vantage
Mon, 10/10/22 - 06:54 pm
biopharma stocks
AbbVie
Alnylam
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eisai
Eli Lilly
GSK
Intellia Therapeutics
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Roche nets FDA approval for HER2-low breast cancer test paired with AstraZeneca-Daiichi's Enhertu
Fierce Biotech
Wed, 10/5/22 - 07:07 pm
Roche
FDA
diagnostics
Medtech
HER2-low breast cancer
Enhertu
AstraZeneca
Daiichi Sankyo
Daiichi Sankyo's Ezharmia Becomes First EZH1/2 Inhibitor for Blood Cancer
BioSpace
Mon, 09/26/22 - 11:32 pm
Daiichi Sankyo
Japan
Ezharmia
relapsed or refractory adult T-cell leukemia/lymphoma
ESMO: Daiichi dazzles in lung cancer to dial up hopes for next ADC
Fierce Biotech
Mon, 09/12/22 - 10:43 am
ESMO
Daiichi Sankyo
DS-7300
small cell lung cancer
Seagen loses arbitration case to Daiichi Sankyo over cancer drug technology
BioPharma Dive
Sun, 08/14/22 - 10:50 pm
Seagen
legal
arbitration
Daiichi Sankyo
FDA approves AstraZeneca, Daiichi drug in breast cancer first
BioPharma Dive
Sun, 08/7/22 - 11:24 pm
AstraZeneca
Daiichi Sankyo
breast cancer
Enhertu
FDA
HER2-low breast cancer
AstraZeneca wins two recommendations, one priority review
Morningstar
Mon, 07/25/22 - 10:54 am
AstraZeneca
Europe
Daiichi Sankyo
Enhertu
breast cancer
Ultomiris
Tezspire
Daiichi Sankyo willfully infringed Seagen patent in creating Enhertu, court rules
Fierce Pharma
Wed, 07/20/22 - 09:58 am
Daiichi Sankyo
Seagen
Enhertu
patents
legal
EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track
Pharmaforum
Mon, 06/13/22 - 10:44 am
Daiichi Sankyo
EHA
quizartinib
clinical trials
acute myeloid leukemia

Pages